Treatment with Takhzyro (lanadelumab) significantly improves health-related quality of life in people with hereditary angioedema (HAE), new data from…
Articles by Marisa Wexler, MS
Assessing C1-inhibitor (C1-INH) activity for the diagnosis and monitoring of hereditary angioedema (HAE) can be done through three distinct…
Preventive treatment with oral berotralstat (BCX7353) significantly lowers the frequency of swelling attacks in people with hereditary angioedema…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
The first documented case of a hereditary angioedema (HAE) attack in an unborn child — whose symptoms resolved after treating…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
Antisense oligonucleotides (ASOs) being developed by Ionis Pharmaceuticals may reduce the frequency of attacks in people with hereditary…
BioCryst Pharmaceuticals is prepared to launch Orladeyo (berotralstat), an oral treatment for hereditary angioedema (HAE), by the…
KalVista Pharmaceuticals anticipates beginning a Phase 2 clinical trial in the second half of this year to test…
Cipla has received final approval from the U.S. Food and Drug Administration (FDA) for a generic version of…